CureVac Announces Changes of CDO – Myriam Mendila to succeed Klaus Edvardsen
- Myriam Mendila appointed as Chief Development Officer starting from February 1, 2023
- Klaus Edvardsen returning to Denmark after holding numerous leadership positions in the U.S. and Europe
- Ulrike Gnad-Vogt, Senior Vice President Area Head Oncology, will act as interim Chief Development Officer
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”) today announced that Chief Development Officer Klaus Edvardsen will leave the company on June 30, 2022. He plans to return home to Denmark for a new professional opportunity. CureVac is pleased to welcome Myriam Mendila to this key role. Myriam’s appointment will take effect on February 1, 2023. Until then, Ulrike Gnad-Vogt, Senior Vice President Area Head Oncology, will act as interim Chief Development Officer.